RNA-Based Cancer Therapies
RNA-based cancer therapies use ribonucleic acid molecules to treat cancer. These approaches target specific genes or instruct the body’s own cells to fight tumours. Unlike traditional chemotherapy, they aim for greater precision and fewer side effects. Researchers continue to develop several types of RNA therapies for different stages of cancer care.
How RNA Therapies Work
Cancer cells often depend on abnormal genes or proteins to grow. RNA therapies interfere with these processes in different ways. Some RNA molecules silence harmful genes so cancer cells stop producing the proteins they need. Others deliver genetic instructions that help the immune system recognise and attack tumours. Still others correct or block faulty RNA signals inside cancer cells. Scientists design these therapies to act mainly on cancer-related targets while sparing healthy tissue.
Main Types of RNA-Based Approaches
Several RNA platforms are under study or already in use.
mRNA Cancer Vaccines
These vaccines carry instructions for tumour-specific proteins. Once injected, cells produce the proteins and display them to the immune system. The immune system then learns to recognise and destroy cancer cells that carry the same markers. Personalised mRNA vaccines can be designed from a patient’s own tumour mutations.
RNA Interference (siRNA and miRNA)
Small interfering RNA (siRNA) and microRNA (miRNA) can silence specific genes. When delivered to cancer cells, they block the production of proteins that drive tumour growth or drug resistance. This approach offers a direct way to switch off oncogenes.
Antisense Oligonucleotides
These short synthetic strands bind to target RNA and prevent it from being translated into protein. They can also trigger the destruction of the harmful RNA. Doctors already use similar molecules for certain non-cancer diseases, and researchers are testing them against cancer genes.
Other Emerging Methods
Scientists are also exploring RNA molecules that activate immune cells or that work with gene-editing tools to correct cancer-related mutations.
Advantages and Challenges
RNA therapies can be designed quickly once a target is identified. They also support personalised treatment because scientists can tailor sequences to individual tumours. In addition, many RNA drugs act only temporarily, which may reduce long-term side effects.
However, delivery remains a major challenge. RNA molecules break down easily in the body, so researchers must protect them and guide them to the right cells. Off-target effects and strong immune reactions can also occur. Scientists are improving lipid nanoparticles and other carriers to solve these problems.
Current Progress
Several RNA-based cancer treatments are advancing through clinical trials. mRNA vaccines for melanoma, lung cancer, and other tumours have shown encouraging immune responses. RNA interference approaches are being tested against hard-to-treat cancers. Regulatory agencies have already approved RNA drugs for other diseases, which has built confidence in the platform.
In summary, RNA-based cancer therapies offer a flexible and precise way to target tumours. Ongoing improvements in delivery and design are expected to expand their use in the coming years.